Organization – Talk Bio

Erasca, Corvus, and BioAge Target $500M+ Offerings Amid Biotech Fundraising Surge

4 days ago talkbio0Tagged BioAge, Corvus, Erasca, Fund Raising, offerings, public entity

Erasca; Corvus; BioAge; biotech offerings; fundraising; public offering

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

2 months ago talkbio0Tagged China, License Agreement, Metabolic Diseases, milestone payments, Obesity, oral small-molecule therapeutics, OXTR gene, Partnership, royalties, strategic collaboration, upfront payment, Zealand Pharma

Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, gene therapy, Gene Writing, Investments, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Regeneron; gene writing; TSRA-196; AATD; alpha-1 antitrypsin deficiency; gene therapy; partnership; investment

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, ARPA-H grant, CAR-T, Clinical Trials, Gene Writing, genome engineering, in vivo, Lipid Nanoparticles, Partnership, Regeneron, Tessera, TSRA-196

Tessera Therapeutics; Gene Writing; in vivo CAR-T; ARPA-H grant; Regeneron partnership; TSRA-196; alpha-1 antitrypsin deficiency; Lipid Nanoparticles; in vivo genome engineering; clinical trials

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2 months ago talkbio0Tagged 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene, Cantor, clinical-stage pharmaceutical, Inhibikase Therapeutics, Jefferies, pre-funded, Pricing, public entity

Inhibikase Therapeutics; public offering; common stock; pre-funded warrants; $100 million; Jefferies; BofA Securities; Cantor; clinical-stage pharmaceutical; pricing

AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

2 months ago talkbio0Tagged AI Proteins, Artificial Intelligence, BioCapital, Biotechnology, de novo miniproteins, Drug Discovery, Religious Missions, Santé Ventures, Series A financing, Synthetic Biology, therapeutic protein

AI Proteins; Series A financing; de novo miniproteins; protein therapeutics; artificial intelligence; drug discovery; Mission BioCapital; Santé Ventures; synthetic biology; biotechnology

PBMs and FTC Battle in Court Over In-House Insulin Pricing Challenge Intensifies

2 months ago talkbio0Tagged administrative proceedings, antitrust lawsuit, Caremark Rx, drug affordability, Express Scripts, Insulin, PBMs, Pricing, rebate schemes, United States Federal Trade Commission

PBMs; FTC; insulin pricing; rebate schemes; antitrust lawsuit; administrative proceedings; drug affordability; Caremark Rx; Express Scripts; OptumRx

Nxera Pharma to Cut 15% of Workforce in Japan and UK as Part of Restructuring Plan

2 months ago talkbio0Tagged GPCR pipeline, Japan, Nxera Pharma, Optimization, Organization administrative structures, profitability, restructuring, Surgical aspects, UK, Workforce reduction

Nxera Pharma; workforce reduction; restructuring; Japan; UK; R&D operations; profitability; GPCR pipeline; organizational optimization

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

2 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Clinical trial failure, GalNAc, Korro Bio, KRRO-110, layoffs, Nordisk, Partnership, Platform, RNA Editing

Korro Bio; KRRO-110; Alpha-1 Antitrypsin Deficiency (AATD); RNA editing; clinical trial failure; layoffs; Novo Nordisk partnership; GalNAc platform; biotech strategy shift

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

3 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development